DURHAM, N.C.–(BUSINESS WIRE)–BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete multiomic view of the cellular ecosystem, from discovery to diagnostics, today announced that it will share a wide range of new research related to its recent single-cell multiomic data, single-cell whole genome sequencing and comprehensive multiomic profiling at the ASHG 2023 Annual Meeting in Washington, D.C.

“Our technology supports scientific discoveries by revealing multiple tiers of dynamic molecular information within ecosystems of individual cells, and we are excited to present our latest groundbreaking advancements in single-cell analysis at ASHG”

Post this

“Our technology supports scientific discoveries by revealing multiple tiers of dynamic molecular information within ecosystems of individual cells, and we are excited to present our latest groundbreaking advancements in single-cell analysis at ASHG,” said Suresh Pisharody, CEO, BioSkryb. “In this research, our in-house scientists and academic collaborators were able to leverage the power of both ResolveDNA® and ResolveOME™ to better understand tumor evolution in breast cancer, cell states in B-Cell Acute Lymphoblastic Leukemia cancer cells and much more. We look forward to highlighting these recent accomplishments amongst our industry colleagues.”

BioSkryb’s presentation schedule at ASHG 2023 is as follows:

• CoLab Sessions
  • Comprehensive multiomic profiling using fluorescence activated cell and nuclei sorting with the Sony SH800 sorter and ResolveOME™ amplification
    • Thursday, November 2, 12:20pm-12:50pm EST, CoLab Theater 2
    • Presenter: Jon S. Zawistowski, Ph.D., Senior Director of R&D, BioSkryb Genomics
    • Description: Pairing Sony SH800 sorting with ResolveOME™ multiomic profiling unlocked the ability to discern somatic mosaicism and tumor evolution. Heterogeneous PIK3CA mutations, copy number alterations, and transcriptional cell states were revealed in single breast cancer cells. Single nucleus sorting in primary neurons, murine brain, and cell lines enabled nuclear transcriptional profiling and quantitation of genomic copy number variation.
  • Single-cell whole genome sequencing charts the co-evolution of genotype and phenotype in pediatric B-ALL
    • Friday, November 3, 3:45pm-4:15pm EST, CoLab Theater 1
    • Presenter: Tamara Prieto, Ph.D., Weill Cornell Medicine & New York Genome Center
    • Description: Single-cell whole genome sequencing and gene expression analysis with ResolveDNA® revealed the co-evolution of surface marker expression and the presence of two different maturation cell states in B-Cell Acute Lymphoblastic Leukemia (B-ALL) cancer cells. It also identified a potential genotype-phenotype association between two deletions in chromosome 6 and a more stem-like state.

• Poster Presentations
  • Thursday, November 2, 3:00pm-5:00pm EST, Exhibit and Poster Hall, Halls A/B
    • PB3439 | Presenter: Dennis Gong| Multiomic single cell analysis of primary pancreatic ductal adenocarcinoma enhanced by fixation
    • PB5185 | Presenter: Tia Tate, Ph.D. | Unveiling Inter- and Intra-Tumor Heterogeneity in Ductal Carcinoma in Situ (DCIS) and Invasive Ductal Carcinoma (IDC) through Integration of Unified Single-Cell Whole Genome Copy Number and RNA Expression Data
    • PB2037 | Presenter: Isai Salas-Gonzalaz, Ph.D. | Quantitative characterization of on-target and off-target variation induced by CRISPR+Cas9 systems at the single-cell resolution
  • Friday, November 3, 3:00pm-5:00pm EST, Exhibit and Poster Hall, Halls A/B
    • PB5024 | Presenter: Joseph Dahl, Ph.D. | Elucidation of tumor clonal diversity in an AML drug resistance model using a high throughput single cell genome amplification method

The BioSkryb team will be located at booth #803 at the conference. To schedule a demo or meeting, please visit the BioSkryb website.

About BioSkryb Genomics

BioSkryb Genomics is a rapidly growing organization that is transforming single cell molecular discovery and analysis. Through its single cell whole genome and whole transcriptome amplification tools, scientists and clinicians can gain an unprecedented view of the genome, transcriptome, and proteome within a single cell to better understand the drivers, mechanisms, and management of complex disease. The company is headquartered in Durham, North Carolina. For more information, visit bioskryb.com.